Agenus Inc  

(Public, NASDAQ:AGEN)   Watch this stock  
Find more results for AGEN
-0.01 (-0.27%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.67 - 3.79
52 week 3.20 - 5.60
Open 3.71
Vol / Avg. 1.16M/2.01M
Mkt cap 321.90M
P/E     -
Div/yield     -
EPS -1.17
Shares 99.74M
Beta 2.11
Inst. own 40%
Nov 7, 2017
Q3 2017 Agenus Inc Earnings Call - Webcast
Sep 26, 2017
Agenus Inc at Ladenburg Thalmann Healthcare Conference
Sep 25, 2017
Agenus Inc at Cantor Fitzgerald Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1096.67% -562.59%
Operating margin -942.55% -476.12%
EBITD margin - -454.20%
Return on average assets -90.72% -63.62%
Return on average equity - -805.04%
Employees 255 -
CDP Score - -


3 Forbes Rd
LEXINGTON, MA 02421-7305
United States - Map
+1-781-6744410 (Phone)
+1-781-6744200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Officers and directors

Garo H. Armen Ph.D. Chairman of the Board, Chief Executive Officer, Founder
Age: 64
Bio & Compensation  - Reuters
Christine M. Klaskin Vice President - Finance
Age: 51
Bio & Compensation  - Reuters
Karen Higgins Valentine General Counsel, Chief Legal Officer
Age: 45
Bio & Compensation  - Reuters
Ozer Baysal Chief Commercial Officer, Head of HR
Age: 61
Bio & Compensation  - Reuters
Jean-Marie Cuillerot M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Brian Corvese Independent Director
Age: 59
Bio & Compensation  - Reuters
Wadih Jordan Independent Director
Age: 82
Bio & Compensation  - Reuters
Shalini Sharp Independent Director
Age: 42
Bio & Compensation  - Reuters
Ulf Wiinberg Independent Director
Age: 58
Bio & Compensation  - Reuters
Timothy R. Wright Independent Director
Age: 59
Bio & Compensation  - Reuters